Guanggong Wang1, Zonglei Zhao1, Shichao Zhao1, Shoukun Ding1, Shuxin Shen1, Lixia Wang2. 1. Department of Cardiology, Henan Provincial People's Hospital (People's Hospital of Zhengzhou University), 7 Weiwu Road, Zhengzhou, 450003, China. 2. Department of Cardiology, Henan Provincial People's Hospital (People's Hospital of Zhengzhou University), 7 Weiwu Road, Zhengzhou, 450003, China. lixiawang1014@126.com.
Abstract
PURPOSE: Although cardiac resynchronization therapy (CRT) has been demonstrated extensively to benefit heart failure (HF) patients with wide QRS complexes, the effect of CRT in patients with narrow QRS complexes remains unclear. This meta-analysis aimed to determine whether HF patients with narrow QRS complexes may benefit from CRT. METHODS: A search of MEDLINE, EMBASE, and Cochrane databases was performed to identify randomized controlled trials (RCTs) that investigated the effect of CRT in HF patients with narrow QRS complexes (< 130 ms). Outcomes included all-cause mortality, heart failure-related death or hospitalization, 6-min walk distance, quality of life ejection fraction, end-systolic volume, and end-diastolic volume. RESULTS: A total of five RCTs involving 1246 HF patients with narrow QRS complexes were included. The frequency of all-cause mortality for patients receiving CRT versus the control group was 10 versus 7 % (relative risk [RR] 1.45, 95 % confidence interval [CI] 1.002 to 2.091, P = 0.049). CRT did not reduce heart failure-related mortality (RR 0.89; 95 % CI 0.52 to 1.54; P = 0.69) or hospitalization (RR 0.99, 95 % CI 0.79 to 1.23, P = 0.91). In addition, CRT did not improve average 6-min walk distance (weighted mean difference [WMD] 39.28 m, 95 % CI -71.04 to 149.61 m, P = 0.49), QOL scores (WMD 0.64 points, 95 % CI -2.15.10 to 3.43 points, P = 0.65), or ejection fraction (WMD 0.90 %, 95 % CI -0.71 to 2.51 %, P = 0.28). CONCLUSIONS: In HF patients with reduced left ventricular ejection fraction (≤ 35 %) and narrow QRS complexes (< 130 ms), CRT did not improve clinical or functional outcomes and may actually increase all-cause mortality.
PURPOSE: Although cardiac resynchronization therapy (CRT) has been demonstrated extensively to benefit heart failure (HF) patients with wide QRS complexes, the effect of CRT in patients with narrow QRS complexes remains unclear. This meta-analysis aimed to determine whether HF patients with narrow QRS complexes may benefit from CRT. METHODS: A search of MEDLINE, EMBASE, and Cochrane databases was performed to identify randomized controlled trials (RCTs) that investigated the effect of CRT in HF patients with narrow QRS complexes (< 130 ms). Outcomes included all-cause mortality, heart failure-related death or hospitalization, 6-min walk distance, quality of life ejection fraction, end-systolic volume, and end-diastolic volume. RESULTS: A total of five RCTs involving 1246 HF patients with narrow QRS complexes were included. The frequency of all-cause mortality for patients receiving CRT versus the control group was 10 versus 7 % (relative risk [RR] 1.45, 95 % confidence interval [CI] 1.002 to 2.091, P = 0.049). CRT did not reduce heart failure-related mortality (RR 0.89; 95 % CI 0.52 to 1.54; P = 0.69) or hospitalization (RR 0.99, 95 % CI 0.79 to 1.23, P = 0.91). In addition, CRT did not improve average 6-min walk distance (weighted mean difference [WMD] 39.28 m, 95 % CI -71.04 to 149.61 m, P = 0.49), QOL scores (WMD 0.64 points, 95 % CI -2.15.10 to 3.43 points, P = 0.65), or ejection fraction (WMD 0.90 %, 95 % CI -0.71 to 2.51 %, P = 0.28). CONCLUSIONS: In HF patients with reduced left ventricular ejection fraction (≤ 35 %) and narrow QRS complexes (< 130 ms), CRT did not improve clinical or functional outcomes and may actually increase all-cause mortality.
Authors: Cheuk-Man Yu; Yat-Sun Chan; Qing Zhang; Gabriel W K Yip; Chi-Kin Chan; Leo C C Kum; LiWen Wu; Alex Pui-Wai Lee; Yat-Yin Lam; Jeffrey Wing-Hong Fung Journal: J Am Coll Cardiol Date: 2006-12-05 Impact factor: 24.094
Authors: Gabe B Bleeker; Martin J Schalij; Sander G Molhoek; Eduard R Holman; Harriette F Verwey; Paul Steendijk; Ernst E van der Wall; Jeroen J Bax Journal: Am J Cardiol Date: 2005-01-01 Impact factor: 2.778
Authors: Shajil Chalil; Berthold Stegemann; Sarkaw Muhyaldeen; Kayvan Khadjooi; Russell E A Smith; Paul J Jordan; Francisco Leyva Journal: J Am Coll Cardiol Date: 2007-06-29 Impact factor: 24.094
Authors: Jean-Claude Daubert; Leslie Saxon; Philip B Adamson; Angelo Auricchio; Ronald D Berger; John F Beshai; Ole Breithard; Michele Brignole; John Cleland; David B DeLurgio; Kenneth Dickstein; Derek V Exner; Michael Gold; Richard A Grimm; David L Hayes; Carsten Israel; Christophe Leclercq; Cecilia Linde; JoAnn Lindenfeld; Bela Merkely; Lluis Mont; Francis Murgatroyd; Frits Prinzen; Samir F Saba; Jerold S Shinbane; Jagmeet Singh; Anthony S Tang; Panos E Vardas; Bruce L Wilkoff; Jose Luis Zamorano; Inder Anand; Carina Blomström-Lundqvist; John P Boehmer; Hugh Calkins; Serge Cazeau; Victoria Delgado; N A Mark Estes; David Haines; Fred Kusumoto; Paco Leyva; Frank Ruschitzka; Lynne Warner Stevenson; Christian Tobias Torp-Pedersen Journal: Europace Date: 2012-09 Impact factor: 5.214
Authors: Jeroen J Bax; Gabe B Bleeker; Thomas H Marwick; Sander G Molhoek; Eric Boersma; Paul Steendijk; Ernst E van der Wall; Martin J Schalij Journal: J Am Coll Cardiol Date: 2004-11-02 Impact factor: 24.094
Authors: Gabe B Bleeker; Eduard R Holman; Paul Steendijk; Eric Boersma; Ernst E van der Wall; Martin J Schalij; Jeroen J Bax Journal: J Am Coll Cardiol Date: 2006-11-09 Impact factor: 24.094
Authors: John F Beshai; Richard A Grimm; Sherif F Nagueh; James H Baker; Scott L Beau; Steven M Greenberg; Luis A Pires; Patrick J Tchou Journal: N Engl J Med Date: 2007-11-06 Impact factor: 91.245